Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Ferriprotoporphyrin IX (FP-IX) polymerization site, located within the acidic food vacuole of Plasmodium parasites, is a critical target for antimalarial therapy (ResearchGate, 2021). During the intraerythrocytic stage, the parasite catabolizes host hemoglobin to obtain essential amino acids, releasing toxic free heme (FP-IX) (NIH, 2017). To survive, the parasite detoxifies FP-IX by sequestering it into an insoluble, inert crystalline polymer known as hemozoin or malaria pigment (NIH, 1999). This biomineralization process is essential for parasite survival and is unique to the parasite, making it an ideal therapeutic target (ResearchGate, 2020). Antimalarial drugs, particularly the quinoline class (e.g., chloroquine and quinine), act by interfering with this detoxification pathway (PNAS, 2019). These drugs accumulate in the acidic food vacuole and bind to heme monomers or the growing faces of hemozoin crystals, effectively capping the crystals and preventing further polymerization (ResearchGate, 1998). The resulting accumulation of free heme or heme-drug complexes is highly toxic, leading to the destruction of the parasite's membranes and its eventual death (YouTube, 2020). This target is highly specific to the parasite, as humans do not possess a similar heme detoxification mechanism (NIH, 2020). Despite its historical success, the utility of drugs targeting this site is increasingly threatened by the emergence of resistant strains, often mediated by mutations in transporters like the Plasmodium falciparum chloroquine resistance transporter (PfCRT) (BioRxiv, 2023). Understanding the molecular interactions at this site remains crucial for the development of next-generation antimalarials to combat drug-resistant malaria (NIH, 2021).
Inhibition of the biocrystallization of toxic ferriprotoporphyrin IX (heme) into insoluble, non-toxic hemozoin crystals within the parasite's acidic food vacuole. Drugs bind to heme monomers or the growing crystal surface, leading to the accumulation of toxic free heme or heme-drug complexes that cause oxidative damage and membrane lysis.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ferriprotoporphyrin IX polymerization.